Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with Chemoradiotherapy in Unresectable Locally Advanced ESCC
NCT06715501Enrolling by invitation
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoints: 2-year progression free survival rate and Incidence of Treatment-Emergent Adverse Events. Started Dec 2024; status: enrolling by invitation.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06715501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715501.